Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 6 Issue 12

Therapeutic Potential of Apixaban Vs Warfarin in Morbidly Obese Patients

Lalita Sandey1, Aditi Bhatt2, Khushbu Singh3, Chhatrapal4, Kamini Verma5 and Jhakeshwar Prasad6*

1LCIT School of Pharmacy, Bodari, Bilaspur, Chhattisgarh, India
2Shri Shankaracharya Technical Campus, Faculty of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, India
3Department of Pharmaceutical Sciences, Shalom Institute of Health and Allied Sciences, Prayagraj, Uttar Pradesh, India
4Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, India
5Shri Shankaracharya Professional University, Junwani, Bhilai, Chhattisgarh, India
6Shri Shankaracharya College of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, India

*Corresponding Author: Jhakeshwar Prasad, Shri Shankaracharya College of Pharmaceutical Sciences, Bhilai, Chhattisgarh, India.

Received: October 13, 2022; Published: November 14, 2022


This study was conducted to evaluate the efficacy and safety of apixaban versus warfarin in morbidly obese patients. A total of 250 morbidly obese patients with a body mass index (BMI) higher than 40 kg/m2 a body weight higher than 120 kg who were on anticoagulation therapy with apixaban or warfarin for over one month were included in the study. This retrospective cohort, multicenter study was executed using the medical records of 125 morbidly obese patients treated with apixaban, while patients on warfarin were selected using a systemic random sampling to match the sample size of the apixaban group. There was no significant difference between apixaban and warfarin in the development of thromboembolic events and major bleeding. However, incidences of minor bleeding significantly decreased in the apixaban group compared to patients treated with warfarin. This difference was overcome by controlling serum creatinine and nonsteroidal anti-inflammatory drugs (NSAIDs). In conclusion, apixaban efficacy and safety are nearly the same as that of warfarin in morbidly obese patients with a lower incidence of minor bleeding with apixaban. Controlling serum creatinine and NSAIDs use may improve warfarin safety and decrease its complications.

Keywords: Efficacy and Safety of Apixaban; NSAIDs; Warfarin Morbidity; Obesity


  1. Chen Ashley., et al. “Direct oral anticoagulant use: a practical guide to common clinical challenges”. Journal of the American Heart Association 9 (2020): 017559.
  2. Burnett AE., et al. “Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment”. Journal of Thrombosis and Thrombolysis 41 (2016): 206-232.
  3. Mandernach MW., et al. “Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review”. Therapeutics and Clinical Risk Management 11 (2015): 1273-1282.
  4. Byon W., et al. “Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review”. Clinical Pharmacokinetics 58 (2019): 1265-1279.
  5. Fava JP., et al. “Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis”. Therapeutic Advances in Drug Safety 9 (2019): 405-414.
  6. Haydara T., et al. “The role of silent helicobacter pylori infection in intragastric ulcers induced by balloon insertion used for management of obesity”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 13 (2019): 116-121.
  7. Kelly T., et al. “Global burden of obesity in 2005 and projections to 2030”. International Journal of Obesity 32 (2008): 1431-1437.
  8. Kushnir M., et al. “Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data”. Lancet Haematology 6 (2019): 359-365.
  9. Pogge E., et al. “Evaluating Prescribing Practices of Apixaban in the Elderly”. The Senior Care Pharmacist 34 (2019): 514-519.
  10. Gruca MM., et al. “Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation”. Journal of Thrombosis and Thrombolysis 48 (2019): 500-505.
  11. Kent AP., et al. “Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation”. Journal of the American College of Cardiology 72 (2018): 255-267.
  12. Agha M and Agha R. “The rising prevalence of obesity: part A: impact on public health”. International Journal of Surgical Oncology (N Y.) 2 (2017): 17.
  13. Deitelzweig S., et al. “Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study”. Journal of Clinical Medicine 9 (2020): 1633.
  14. Sugerman HJ. “Effects of increased intra-abdominal pressure in severe obesity”. Surgical Clinics of North America 81 (2001): 1063-1075.
  15. Russo I. “The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance”. Scientifica (2012): 525374.
  16. Vyas V and Lambiase P. “Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology and Novel Therapeutic Opportunities”. Arrhythmia and Electrophysiology Review 8 (2019): 28-36.
  17. Ghattas KN., et al. “Obesity and Atrial Fibrillation: Should We Screen for Atrial Fibrillation in Obese Individuals? A Comprehensive Review”. Cureus 12 (2020): 10471.
  18. Yun C., et al. “Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI ≥40”. Blood 130 (2017): 1105.
  19. Kido K., et al. “Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation”. Annals of Pharmacotherapy 53 (2019): 165-170.
  20. Elshafei MN., et al. “Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis”. Journal of Thrombosis and Thrombolysis 51 (2021): 388-396.
  21. Cohen A., et al. “Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity”. Journal of Clinical Medicine 10 (2021): 200.
  22. Kjerpeseth LJ., et al. “Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study”. PLoS One 14 (2019): 0221500.
  23. Gui YY., et al. “The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients: A systemic review and meta-analysis”. Medicine (2019): e18205.
  24. Weber J., et al. “The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature”. European Journal of Haematology 102 (2019): 312-318.
  25. Hanni C., et al. “Outcomes associated with apixaban vs warfarin in patients with renal dysfunction”. Blood Advances 4 (2020): 2366-2371.
  26. Moore N., et al. “Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs”. Therapeutics and Clinical Risk Management 11 (2015): 1061-75.
  27. Villa Zapata L., et al. “Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis”. Thrombosis and Haemostasis 120 (2020): 1066-1074.


Citation: Jhakeshwar Prasad., et al. “Therapeutic Potential of Apixaban Vs Warfarin in Morbidly Obese Patients". Acta Scientific Pharmaceutical Sciences 6.12 (2022): 05-11.


Copyright: © 2022 Jhakeshwar Prasad., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

Contact US